Trend of A-share and Hong Kong stock innovative drug sector this week
In the third week of January 2022, a total of 10 stocks in the innovative drug sector in mainland and Hong Kong rose and 37 stocks fell. Among them, the top three gainers were Geli pharmaceutical-b (+ 18.53%), Fuhong hanlin-b (+ 11.53%), Yongtai biology-b (+ 9.63%). The top three declines were Yunding xinyao-b (- 13.50%), Hunan Nucien Pharmaceutical Co.Ltd(688189) (- 13.23%) and Rongchang bio-b (- 11.42%). This week, the A-share innovative medicine sector fell 3.16%, outperforming the CSI 300 index by 1.11pp, and biomedicine fell 8.40%. In the past six months, A-share innovative drugs fell by 19.29%, underperforming the Shanghai and Shenzhen 300 index by 5.95pp, and biomedicine fell by 33.79%. This week, the innovative medicine sector of Hong Kong stocks fell 1.00%, outperforming the Hang Seng Index by 2.39pp, and Hang Seng healthcare fell 1.63%. Over the past six months, innovative drugs in Hong Kong stocks have fallen by 14.55%, underperforming the Hang Seng Index by 8.65pp, and Hang Seng health care has fallen by 39.81%.
Progress of key innovative drugs in China
This week, no new drugs were approved for marketing in China, four NDA were approved by nmpa and four ind were approved by FDA.
Progress of overseas key innovative drugs
This week, two overseas drugs were approved by MHLW, five ind applications were approved by FDA and one drug was approved by PMDA.
Weekly special topic – research progress of EGFR double antibody
A total of 35 EGFR dual antibodies are under development in the world, of which 1 is approved for listing, 1 is in phase II / III clinical and 6 are in phase I / II clinical. A total of 15 EGFR dual antibodies are under development in China, of which Johnson & Johnson’s products are in phase III clinical trials. The EGFR double antibodies of shore vein biology and Betta Pharmaceuticals Co.Ltd(300558) are in phase I / II clinical, with the fastest progress among Chinese companies. In terms of target distribution, EGFR / CD3 has the largest number of dual antibodies in research, followed by EGFR / c-Met. Both Betta Pharmaceuticals Co.Ltd(300558) and Betta Pharmaceuticals Co.Ltd(300558) are EGFR / c-Met dual antibodies.
Progress of global key innovative drug transactions this week
There were 10 key transactions in the world this week, and there were 3 key transactions with disclosed amount. 1) The company cooperates with Xingyi Onda in the development of immune cell therapy drugs. 2) Abbisko therapeutics announced a global partnership with Lilly to discover and develop new molecules. 3) Evotec and Eli Lilly cooperate in drug discovery in the field of metabolic diseases.
Risk warning: expected risk of drug price reduction; The implementation progress of medical reform policy is lower than the expected risk; Risk of R & D failure.
